Multidrug-resistant HIV viral rebound during early syphilis: a case report
Background Syphilis has been associated with an increase in HIV RNA and a temporary decline in CD4 T cell counts in people living with HIV who are not receiving antiretroviral treatment (ART), and may be associated with a transient HIV RNA rebound in those who are receiving ART. Our case is the firs...
Saved in:
| Published in: | BMC infectious diseases Vol. 20; no. 1; pp. 273 - 5 |
|---|---|
| Main Authors: | , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
London
BioMed Central
07.04.2020
BioMed Central Ltd Springer Nature B.V BMC |
| Subjects: | |
| ISSN: | 1471-2334, 1471-2334 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Background
Syphilis has been associated with an increase in HIV RNA and a temporary decline in CD4 T cell counts in people living with HIV who are not receiving antiretroviral treatment (ART), and may be associated with a transient HIV RNA rebound in those who are receiving ART. Our case is the first to highlight the risk of a multidrug-resistant HIV viral rebound during the course of early syphilis even if antiretroviral drug concentrations are within the therapeutic range.
Case presentation
This 50-year-old HIV-1-positive male patient with concomitant early syphilis presented with an HIV RNA rebound (8908 copies/mL) during a scheduled visit to our clinic. He was receiving a stable ART regimen consisting of darunavir/cobicistat plus dolutegravir, and had a 15-year history of viral suppression. Good short-term drug adherence could be inferred as liquid chromatography tandem mass spectrometry showed that his trough antiretroviral drug concentrations were within the therapeutic range: darunavir 2353 ng/mL (minimum effective concentration > 500 ng/mL) and dolutegravir 986 ng/mL (minimum effective concentration > 100 ng/mL). A plasma RNA genotype resistance test revealed wild-type virus in the integrase region and protease region (PR), but extensive resistance in the reverse transcriptase (RT) region (M41L, E44D, D67N, K70R, M184V, L210W and T215Y). Phylogenetic analysis of next-generation sequences (used to investigate the presence of minor viral variants), the PR and RT sequences from plasma HIV RNA and pro-viral DNA extracted from peripheral blood mononuclear cells during the viral rebound, and a Sanger sequence obtained during a previous virological failure suggested clonal viral expression because the previous PR resistance mutations had been lost or had not been archived in pro-viral DNA.
Conclusions
This case shows that early syphilis may cause an HIV RNA rebound in patients under stable virological control with the potential of transmitting an extensively drug-resistant virus. |
|---|---|
| AbstractList | Syphilis has been associated with an increase in HIV RNA and a temporary decline in CD4 T cell counts in people living with HIV who are not receiving antiretroviral treatment (ART), and may be associated with a transient HIV RNA rebound in those who are receiving ART. Our case is the first to highlight the risk of a multidrug-resistant HIV viral rebound during the course of early syphilis even if antiretroviral drug concentrations are within the therapeutic range. This case shows that early syphilis may cause an HIV RNA rebound in patients under stable virological control with the potential of transmitting an extensively drug-resistant virus. Abstract Background Syphilis has been associated with an increase in HIV RNA and a temporary decline in CD4 T cell counts in people living with HIV who are not receiving antiretroviral treatment (ART), and may be associated with a transient HIV RNA rebound in those who are receiving ART. Our case is the first to highlight the risk of a multidrug-resistant HIV viral rebound during the course of early syphilis even if antiretroviral drug concentrations are within the therapeutic range. Case presentation This 50-year-old HIV-1-positive male patient with concomitant early syphilis presented with an HIV RNA rebound (8908 copies/mL) during a scheduled visit to our clinic. He was receiving a stable ART regimen consisting of darunavir/cobicistat plus dolutegravir, and had a 15-year history of viral suppression. Good short-term drug adherence could be inferred as liquid chromatography tandem mass spectrometry showed that his trough antiretroviral drug concentrations were within the therapeutic range: darunavir 2353 ng/mL (minimum effective concentration > 500 ng/mL) and dolutegravir 986 ng/mL (minimum effective concentration > 100 ng/mL). A plasma RNA genotype resistance test revealed wild-type virus in the integrase region and protease region (PR), but extensive resistance in the reverse transcriptase (RT) region (M41L, E44D, D67N, K70R, M184V, L210W and T215Y). Phylogenetic analysis of next-generation sequences (used to investigate the presence of minor viral variants), the PR and RT sequences from plasma HIV RNA and pro-viral DNA extracted from peripheral blood mononuclear cells during the viral rebound, and a Sanger sequence obtained during a previous virological failure suggested clonal viral expression because the previous PR resistance mutations had been lost or had not been archived in pro-viral DNA. Conclusions This case shows that early syphilis may cause an HIV RNA rebound in patients under stable virological control with the potential of transmitting an extensively drug-resistant virus. Background Syphilis has been associated with an increase in HIV RNA and a temporary decline in CD4 T cell counts in people living with HIV who are not receiving antiretroviral treatment (ART), and may be associated with a transient HIV RNA rebound in those who are receiving ART. Our case is the first to highlight the risk of a multidrug-resistant HIV viral rebound during the course of early syphilis even if antiretroviral drug concentrations are within the therapeutic range. Case presentation This 50-year-old HIV-1-positive male patient with concomitant early syphilis presented with an HIV RNA rebound (8908 copies/mL) during a scheduled visit to our clinic. He was receiving a stable ART regimen consisting of darunavir/cobicistat plus dolutegravir, and had a 15-year history of viral suppression. Good short-term drug adherence could be inferred as liquid chromatography tandem mass spectrometry showed that his trough antiretroviral drug concentrations were within the therapeutic range: darunavir 2353 ng/mL (minimum effective concentration > 500 ng/mL) and dolutegravir 986 ng/mL (minimum effective concentration > 100 ng/mL). A plasma RNA genotype resistance test revealed wild-type virus in the integrase region and protease region (PR), but extensive resistance in the reverse transcriptase (RT) region (M41L, E44D, D67N, K70R, M184V, L210W and T215Y). Phylogenetic analysis of next-generation sequences (used to investigate the presence of minor viral variants), the PR and RT sequences from plasma HIV RNA and pro-viral DNA extracted from peripheral blood mononuclear cells during the viral rebound, and a Sanger sequence obtained during a previous virological failure suggested clonal viral expression because the previous PR resistance mutations had been lost or had not been archived in pro-viral DNA. Conclusions This case shows that early syphilis may cause an HIV RNA rebound in patients under stable virological control with the potential of transmitting an extensively drug-resistant virus. Syphilis has been associated with an increase in HIV RNA and a temporary decline in CD4 T cell counts in people living with HIV who are not receiving antiretroviral treatment (ART), and may be associated with a transient HIV RNA rebound in those who are receiving ART. Our case is the first to highlight the risk of a multidrug-resistant HIV viral rebound during the course of early syphilis even if antiretroviral drug concentrations are within the therapeutic range.BACKGROUNDSyphilis has been associated with an increase in HIV RNA and a temporary decline in CD4 T cell counts in people living with HIV who are not receiving antiretroviral treatment (ART), and may be associated with a transient HIV RNA rebound in those who are receiving ART. Our case is the first to highlight the risk of a multidrug-resistant HIV viral rebound during the course of early syphilis even if antiretroviral drug concentrations are within the therapeutic range.This 50-year-old HIV-1-positive male patient with concomitant early syphilis presented with an HIV RNA rebound (8908 copies/mL) during a scheduled visit to our clinic. He was receiving a stable ART regimen consisting of darunavir/cobicistat plus dolutegravir, and had a 15-year history of viral suppression. Good short-term drug adherence could be inferred as liquid chromatography tandem mass spectrometry showed that his trough antiretroviral drug concentrations were within the therapeutic range: darunavir 2353 ng/mL (minimum effective concentration > 500 ng/mL) and dolutegravir 986 ng/mL (minimum effective concentration > 100 ng/mL). A plasma RNA genotype resistance test revealed wild-type virus in the integrase region and protease region (PR), but extensive resistance in the reverse transcriptase (RT) region (M41L, E44D, D67N, K70R, M184V, L210W and T215Y). Phylogenetic analysis of next-generation sequences (used to investigate the presence of minor viral variants), the PR and RT sequences from plasma HIV RNA and pro-viral DNA extracted from peripheral blood mononuclear cells during the viral rebound, and a Sanger sequence obtained during a previous virological failure suggested clonal viral expression because the previous PR resistance mutations had been lost or had not been archived in pro-viral DNA.CASE PRESENTATIONThis 50-year-old HIV-1-positive male patient with concomitant early syphilis presented with an HIV RNA rebound (8908 copies/mL) during a scheduled visit to our clinic. He was receiving a stable ART regimen consisting of darunavir/cobicistat plus dolutegravir, and had a 15-year history of viral suppression. Good short-term drug adherence could be inferred as liquid chromatography tandem mass spectrometry showed that his trough antiretroviral drug concentrations were within the therapeutic range: darunavir 2353 ng/mL (minimum effective concentration > 500 ng/mL) and dolutegravir 986 ng/mL (minimum effective concentration > 100 ng/mL). A plasma RNA genotype resistance test revealed wild-type virus in the integrase region and protease region (PR), but extensive resistance in the reverse transcriptase (RT) region (M41L, E44D, D67N, K70R, M184V, L210W and T215Y). Phylogenetic analysis of next-generation sequences (used to investigate the presence of minor viral variants), the PR and RT sequences from plasma HIV RNA and pro-viral DNA extracted from peripheral blood mononuclear cells during the viral rebound, and a Sanger sequence obtained during a previous virological failure suggested clonal viral expression because the previous PR resistance mutations had been lost or had not been archived in pro-viral DNA.This case shows that early syphilis may cause an HIV RNA rebound in patients under stable virological control with the potential of transmitting an extensively drug-resistant virus.CONCLUSIONSThis case shows that early syphilis may cause an HIV RNA rebound in patients under stable virological control with the potential of transmitting an extensively drug-resistant virus. Background Syphilis has been associated with an increase in HIV RNA and a temporary decline in CD4 T cell counts in people living with HIV who are not receiving antiretroviral treatment (ART), and may be associated with a transient HIV RNA rebound in those who are receiving ART. Our case is the first to highlight the risk of a multidrug-resistant HIV viral rebound during the course of early syphilis even if antiretroviral drug concentrations are within the therapeutic range. Case presentation This 50-year-old HIV-1-positive male patient with concomitant early syphilis presented with an HIV RNA rebound (8908 copies/mL) during a scheduled visit to our clinic. He was receiving a stable ART regimen consisting of darunavir/cobicistat plus dolutegravir, and had a 15-year history of viral suppression. Good short-term drug adherence could be inferred as liquid chromatography tandem mass spectrometry showed that his trough antiretroviral drug concentrations were within the therapeutic range: darunavir 2353 ng/mL (minimum effective concentration > 500 ng/mL) and dolutegravir 986 ng/mL (minimum effective concentration > 100 ng/mL). A plasma RNA genotype resistance test revealed wild-type virus in the integrase region and protease region (PR), but extensive resistance in the reverse transcriptase (RT) region (M41L, E44D, D67N, K70R, M184V, L210W and T215Y). Phylogenetic analysis of next-generation sequences (used to investigate the presence of minor viral variants), the PR and RT sequences from plasma HIV RNA and pro-viral DNA extracted from peripheral blood mononuclear cells during the viral rebound, and a Sanger sequence obtained during a previous virological failure suggested clonal viral expression because the previous PR resistance mutations had been lost or had not been archived in pro-viral DNA. Conclusions This case shows that early syphilis may cause an HIV RNA rebound in patients under stable virological control with the potential of transmitting an extensively drug-resistant virus. Keywords: Syphilis, Transmitted drug resistance, Virological rebound, HIV prevention, Therapeutic drug monitoring, Case report Syphilis has been associated with an increase in HIV RNA and a temporary decline in CD4 T cell counts in people living with HIV who are not receiving antiretroviral treatment (ART), and may be associated with a transient HIV RNA rebound in those who are receiving ART. Our case is the first to highlight the risk of a multidrug-resistant HIV viral rebound during the course of early syphilis even if antiretroviral drug concentrations are within the therapeutic range. This 50-year-old HIV-1-positive male patient with concomitant early syphilis presented with an HIV RNA rebound (8908 copies/mL) during a scheduled visit to our clinic. He was receiving a stable ART regimen consisting of darunavir/cobicistat plus dolutegravir, and had a 15-year history of viral suppression. Good short-term drug adherence could be inferred as liquid chromatography tandem mass spectrometry showed that his trough antiretroviral drug concentrations were within the therapeutic range: darunavir 2353 ng/mL (minimum effective concentration > 500 ng/mL) and dolutegravir 986 ng/mL (minimum effective concentration > 100 ng/mL). A plasma RNA genotype resistance test revealed wild-type virus in the integrase region and protease region (PR), but extensive resistance in the reverse transcriptase (RT) region (M41L, E44D, D67N, K70R, M184V, L210W and T215Y). Phylogenetic analysis of next-generation sequences (used to investigate the presence of minor viral variants), the PR and RT sequences from plasma HIV RNA and pro-viral DNA extracted from peripheral blood mononuclear cells during the viral rebound, and a Sanger sequence obtained during a previous virological failure suggested clonal viral expression because the previous PR resistance mutations had been lost or had not been archived in pro-viral DNA. This case shows that early syphilis may cause an HIV RNA rebound in patients under stable virological control with the potential of transmitting an extensively drug-resistant virus. Background Syphilis has been associated with an increase in HIV RNA and a temporary decline in CD4 T cell counts in people living with HIV who are not receiving antiretroviral treatment (ART), and may be associated with a transient HIV RNA rebound in those who are receiving ART. Our case is the first to highlight the risk of a multidrug-resistant HIV viral rebound during the course of early syphilis even if antiretroviral drug concentrations are within the therapeutic range. Case presentation This 50-year-old HIV-1-positive male patient with concomitant early syphilis presented with an HIV RNA rebound (8908 copies/mL) during a scheduled visit to our clinic. He was receiving a stable ART regimen consisting of darunavir/cobicistat plus dolutegravir, and had a 15-year history of viral suppression. Good short-term drug adherence could be inferred as liquid chromatography tandem mass spectrometry showed that his trough antiretroviral drug concentrations were within the therapeutic range: darunavir 2353 ng/mL (minimum effective concentration > 500 ng/mL) and dolutegravir 986 ng/mL (minimum effective concentration > 100 ng/mL). A plasma RNA genotype resistance test revealed wild-type virus in the integrase region and protease region (PR), but extensive resistance in the reverse transcriptase (RT) region (M41L, E44D, D67N, K70R, M184V, L210W and T215Y). Phylogenetic analysis of next-generation sequences (used to investigate the presence of minor viral variants), the PR and RT sequences from plasma HIV RNA and pro-viral DNA extracted from peripheral blood mononuclear cells during the viral rebound, and a Sanger sequence obtained during a previous virological failure suggested clonal viral expression because the previous PR resistance mutations had been lost or had not been archived in pro-viral DNA. Conclusions This case shows that early syphilis may cause an HIV RNA rebound in patients under stable virological control with the potential of transmitting an extensively drug-resistant virus. |
| ArticleNumber | 273 |
| Audience | Academic |
| Author | Gervasoni, Cristina Mancon, Alessandro Giacomelli, Andrea Micheli, Valeria Cattaneo, Dario |
| Author_xml | – sequence: 1 givenname: Andrea surname: Giacomelli fullname: Giacomelli, Andrea email: andrea.giacomelli@unimi.it organization: Department of Biomedical and Clinical Sciences, DIBIC Luigi Sacco, Milan University, III Infectious Disease Unit, ASST Fatebenefratelli Sacco University Hospital – sequence: 2 givenname: Valeria surname: Micheli fullname: Micheli, Valeria organization: Clinical Microbiology, Virology and Bioemergencies, ASST Fatebenefratelli Sacco University Hospital – sequence: 3 givenname: Dario surname: Cattaneo fullname: Cattaneo, Dario organization: Gestione Ambulatoriale Politerapie (GAP) Outpatient Clinic, ASST Fatebenefratelli Sacco University Hospital, Unit of Clinical Pharmacology, ASST Fatebenefratelli Sacco University Hospital – sequence: 4 givenname: Alessandro surname: Mancon fullname: Mancon, Alessandro organization: Clinical Microbiology, Virology and Bioemergencies, ASST Fatebenefratelli Sacco University Hospital – sequence: 5 givenname: Cristina surname: Gervasoni fullname: Gervasoni, Cristina organization: III Infectious Disease Unit, ASST Fatebenefratelli Sacco University Hospital, Gestione Ambulatoriale Politerapie (GAP) Outpatient Clinic, ASST Fatebenefratelli Sacco University Hospital |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32264923$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkl1rFDEYhQep2A_9A17IgDd6MTVfkw8vhFLUrlQKWnobMpl3pllmJ9skU9x_b7bb6m6RIrlIePOcE3I4h8Xe6EcoitcYHWMs-YeIiRSqQgRViCmlKvasOMBM4IpQyva2zvvFYYxzhLCQRL0o9ikhnClCD4pv36chuTZMfRUgupjMmMqz2VV564IZygCNn8a2bKfgxr4EE4ZVGVfLaze4-LE0pTURMrX0Ib0snndmiPDqfj8qLr98vjw9q84vvs5OT84ry0WdKmhA1UZSWTe1laQTAoThitcdZUw1SjHbSmmEVcbWhqoGNR1BUjLZWZIHR8VsY9t6M9fL4BYmrLQ3Tt8NfOi1CcnZATS3dUsb1BLeAjMEG0EaA1TwmhJOKWSvTxuv5dQsoLUwpvzrHdPdm9Fd697faoEZolJlg3f3BsHfTBCTXrhoYRjMCH6KmlApOONEooy-fYTO_RTGnFSmFCaqJniL6k3-gBs7n9-1a1N9womgRCnMMnX8DyqvFhbO5pZ0Ls93BO93BJlJ8Cv1ZopRz37--H_24mqXfbMd4J_kHgqWAbkBbPAxBui0dckk59d5ukFjpNdd1psu69xlfddlvfYmj6QP7k-K6EYUl-vGQvib8hOq388NAsI |
| CitedBy_id | crossref_primary_10_1097_QAI_0000000000002749 crossref_primary_10_4102_jphia_v16i1_1324 crossref_primary_10_1089_aid_2024_0035 crossref_primary_10_1111_jdv_18627 |
| Cites_doi | 10.1128/JVI.72.10.7772-7784.1998 10.1097/00002030-200207260-00009 10.1097/QAD.0b013e32832ba8ec 10.1097/QAI.0000000000001962 10.1001/jama.2018.21167 10.1016/S2352-3018(19)30030-X 10.1001/archinternmed.2012.2706 10.1093/cid/ciy182 10.1128/AAC.48.2.644-647.2004 10.1056/NEJM200003303421303 10.1016/S0140-6736(19)30418-0 10.1097/00002030-200203080-00004 10.1016/S1473-3099(13)70066-5 10.1097/00002030-200410210-00012 10.1086/431682 10.1186/s12879-018-3038-4 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2020 COPYRIGHT 2020 BioMed Central Ltd. 2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2020 – notice: COPYRIGHT 2020 BioMed Central Ltd. – notice: 2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM IOV ISR 3V. 7QL 7T2 7U9 7X7 7XB 88E 8C1 8FI 8FJ 8FK ABUWG AEUYN AFKRA AZQEC BENPR C1K CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P M7N PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI 7X8 5PM DOA |
| DOI | 10.1186/s12879-020-04999-4 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Opposing Viewpoints Gale In Context: Science ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Health and Safety Science Abstracts (Full archive) Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Public Health Database ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central Environmental Sciences and Pollution Management ProQuest One ProQuest Central Korea Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Environmental Sciences and Pollution Management ProQuest Central ProQuest One Sustainability ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Health & Medical Research Collection AIDS and Cancer Research Abstracts Health & Safety Science Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health Virology and AIDS Abstracts ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: ProQuest Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1471-2334 |
| EndPage | 5 |
| ExternalDocumentID | oai_doaj_org_article_6c5d3b0d26de4a21a72bae376532633e PMC7140389 A627329914 32264923 10_1186_s12879_020_04999_4 |
| Genre | Journal Article Case Reports |
| GeographicLocations | Germany |
| GeographicLocations_xml | – name: Germany |
| GroupedDBID | --- 0R~ 23N 2WC 53G 5VS 6J9 6PF 7X7 88E 8C1 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABUWG ACGFO ACGFS ACIHN ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AEUYN AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR IOV ISR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS UKHRP W2D WOQ WOW XSB AAYXX AFFHD CITATION ALIPV CGR CUY CVF ECM EIF NPM 3V. 7QL 7T2 7U9 7XB 8FK AZQEC C1K DWQXO H94 K9. M7N PKEHL PQEST PQUKI 7X8 5PM |
| ID | FETCH-LOGICAL-c675t-ebe95a8385b5c82f77e7a6965f3449b994cd88a7c9ac5a39b0bf208848fc25a3 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 8 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000526233300001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1471-2334 |
| IngestDate | Mon Nov 10 04:24:11 EST 2025 Tue Nov 04 01:52:07 EST 2025 Sun Nov 09 12:59:54 EST 2025 Mon Oct 06 18:29:31 EDT 2025 Tue Nov 11 10:19:19 EST 2025 Tue Nov 04 17:58:33 EST 2025 Thu Nov 13 15:07:57 EST 2025 Thu Nov 13 14:52:48 EST 2025 Mon Jul 21 05:47:44 EDT 2025 Tue Nov 18 21:47:01 EST 2025 Sat Nov 29 03:14:06 EST 2025 Sat Sep 06 07:26:44 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Therapeutic drug monitoring Transmitted drug resistance Case report HIV prevention Virological rebound Syphilis |
| Language | English |
| License | Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c675t-ebe95a8385b5c82f77e7a6965f3449b994cd88a7c9ac5a39b0bf208848fc25a3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Report-3 ObjectType-Case Study-4 ObjectType-Case Study-2 ObjectType-Feature-4 content type line 23 ObjectType-Report-1 ObjectType-Article-3 |
| OpenAccessLink | https://doaj.org/article/6c5d3b0d26de4a21a72bae376532633e |
| PMID | 32264923 |
| PQID | 2391295210 |
| PQPubID | 42582 |
| PageCount | 5 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_6c5d3b0d26de4a21a72bae376532633e pubmedcentral_primary_oai_pubmedcentral_nih_gov_7140389 proquest_miscellaneous_2387646280 proquest_journals_2391295210 gale_infotracmisc_A627329914 gale_infotracacademiconefile_A627329914 gale_incontextgauss_ISR_A627329914 gale_incontextgauss_IOV_A627329914 pubmed_primary_32264923 crossref_citationtrail_10_1186_s12879_020_04999_4 crossref_primary_10_1186_s12879_020_04999_4 springer_journals_10_1186_s12879_020_04999_4 |
| PublicationCentury | 2000 |
| PublicationDate | 2020-04-07 |
| PublicationDateYYYYMMDD | 2020-04-07 |
| PublicationDate_xml | – month: 04 year: 2020 text: 2020-04-07 day: 07 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | BMC infectious diseases |
| PublicationTitleAbbrev | BMC Infect Dis |
| PublicationTitleAlternate | BMC Infect Dis |
| PublicationYear | 2020 |
| Publisher | BioMed Central BioMed Central Ltd Springer Nature B.V BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: Springer Nature B.V – name: BMC |
| References | K Buchacz (4999_CR3) 2004; 18 R Lang (4999_CR1) 2018; 18 RW Eisinger (4999_CR5) 2019; 321 EM Gardner (4999_CR11) 2009; 23 MW Traeger (4999_CR2) 2018; 67 SK Calabrese (4999_CR7) 2019; 6 MA Kolber (4999_CR10) 2002; 16 DM Smith (4999_CR13) 2005; 192 AJ Rodger (4999_CR6) 2019; 393 AVG GrewalR (4999_CR12) 2019; 80 M Wirden (4999_CR15) 2004; 48 MA Ostrowski (4999_CR8) 1998; 72 AD Redd (4999_CR14) 2013; 13 W Jarzebowski (4999_CR4) 2012; 172 PJ Easterbrook (4999_CR9) 2002; 16 TC Quinn (4999_CR16) 2000; 342 |
| References_xml | – volume: 72 start-page: 7772 year: 1998 ident: 4999_CR8 publication-title: J Virol doi: 10.1128/JVI.72.10.7772-7784.1998 – volume: 16 start-page: 1521 year: 2002 ident: 4999_CR9 publication-title: AIDS doi: 10.1097/00002030-200207260-00009 – volume: 23 start-page: 1035 year: 2009 ident: 4999_CR11 publication-title: AIDS. doi: 10.1097/QAD.0b013e32832ba8ec – volume: 80 start-page: 585 year: 2019 ident: 4999_CR12 publication-title: J Acquir Immune Defic Syndr doi: 10.1097/QAI.0000000000001962 – volume: 321 start-page: 451 year: 2019 ident: 4999_CR5 publication-title: JAMA doi: 10.1001/jama.2018.21167 – volume: 6 start-page: e211 year: 2019 ident: 4999_CR7 publication-title: Lancet HIV doi: 10.1016/S2352-3018(19)30030-X – volume: 172 start-page: 1237 year: 2012 ident: 4999_CR4 publication-title: Arch Intern Med doi: 10.1001/archinternmed.2012.2706 – volume: 67 start-page: 676 year: 2018 ident: 4999_CR2 publication-title: Clin Infect Dis doi: 10.1093/cid/ciy182 – volume: 48 start-page: 644 year: 2004 ident: 4999_CR15 publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.48.2.644-647.2004 – volume: 342 start-page: 921 year: 2000 ident: 4999_CR16 publication-title: N Engl J Med doi: 10.1056/NEJM200003303421303 – volume: 393 start-page: 2428 year: 2019 ident: 4999_CR6 publication-title: Lancet. doi: 10.1016/S0140-6736(19)30418-0 – volume: 16 start-page: 537 year: 2002 ident: 4999_CR10 publication-title: AIDS. doi: 10.1097/00002030-200203080-00004 – volume: 13 start-page: 622 year: 2013 ident: 4999_CR14 publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(13)70066-5 – volume: 18 start-page: 2075 year: 2004 ident: 4999_CR3 publication-title: AIDS. doi: 10.1097/00002030-200410210-00012 – volume: 192 start-page: 438 year: 2005 ident: 4999_CR13 publication-title: J Infect Dis doi: 10.1086/431682 – volume: 18 start-page: 125 year: 2018 ident: 4999_CR1 publication-title: BMC Infect Dis doi: 10.1186/s12879-018-3038-4 |
| SSID | ssj0017829 |
| Score | 2.306327 |
| Snippet | Background
Syphilis has been associated with an increase in HIV RNA and a temporary decline in CD4 T cell counts in people living with HIV who are not... Syphilis has been associated with an increase in HIV RNA and a temporary decline in CD4 T cell counts in people living with HIV who are not receiving... Background Syphilis has been associated with an increase in HIV RNA and a temporary decline in CD4 T cell counts in people living with HIV who are not... Abstract Background Syphilis has been associated with an increase in HIV RNA and a temporary decline in CD4 T cell counts in people living with HIV who are not... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 273 |
| SubjectTerms | Acquired immune deficiency syndrome AIDS Analysis Anti-HIV Agents - therapeutic use Antiretroviral agents Antiretroviral drugs Antiretroviral therapy Case Report Case reports CD4 antigen Coinfection Darunavir Darunavir - therapeutic use Deoxyribonucleic acid Disease resistance Disease transmission DNA DNA polymerases DNA sequencing Dolutegravir Drug resistance Drug Resistance, Multiple, Viral - genetics Efavirenz Gene sequencing Genetic testing Genotypes Health aspects Heterocyclic Compounds, 3-Ring - therapeutic use Highly active antiretroviral therapy HIV HIV and co-infections HIV Infections - complications HIV Infections - drug therapy HIV Infections - virology HIV prevention HIV-1 - genetics Human immunodeficiency virus Humans Infections Infectious Diseases Influenza Integrase Internal Medicine Leukocytes (mononuclear) Leukocytes, Mononuclear - virology Liquid chromatography Lymphocytes Lymphocytes T Male Mass spectrometry Mass spectroscopy Medical Microbiology Medicine Medicine & Public Health Microbial drug resistance Middle Aged Multidrug resistance Multidrug resistant organisms Mutation Next-generation sequencing Nucleotide sequence Parasitology Patient compliance Patients Peripheral blood mononuclear cells Phylogenetics Phylogeny Proteases Ribonucleic acid RNA RNA, Viral - blood RNA-directed DNA polymerase Sexual and Gender Minorities Sexually transmitted disease prevention Sexually transmitted diseases STD Syphilis Syphilis - complications Syphilis - microbiology T cells Therapeutic drug monitoring Transmitted drug resistance Treponema pallidum Tropical Medicine Viral Load - drug effects Virological rebound Viruses |
| SummonAdditionalLinks | – databaseName: Public Health Database dbid: 8C1 link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELagIMSF9yNQkEFIHMBqYjt-cEGlomqRKAiqqjfLdpKlUpVdNrtI_HtmnOyWFLUXrvFYij1P2zPfEPJK5jHkqpFMBamZjMoz7xvUK6FM7ivfiCY1m9AHB-b42H4dLty6Ia1yZROToa6mEe_It7iw4JrA2eTvZz8Zdo3C19WhhcZVcq3guUTFNDvrFI8CvJ9dFcoYtdWBLdaW4YEpBfpMjpxRwuz_1zL_5ZrOp02eeztNLmn39v8u5g65NQSjdLuXnrvkSt3eIzc-D8_t98mnVJ5bzZcTBqdyjDTbBd3bP6KYGXxK52Crlm1F-1JHWiNWMu1-z_COpntHPY3gImn_KvGAHO5-PNzZY0PzBRbhDLFgwFxbeiNMGcpoeKN1rb2yqmyElDZYK2NljNfR-lh6YUMeGg4mS5omcvjwkGy007Z-TGjpdYVAhVGoKIMIRgmeR58XpvJchzIjxYoJLg7A5Ngf49SlA4pRrmecA8a5xDgnM_JmPWfWw3JcSv0BebumREjt9GE6n7hBQ52KZSVCXnFV1dLzwmsefA32t4QIV4g6Iy9RMhyCZrSYlTPxy65z-1-O3LaCIBD8eiEvIvr-bUT0eiBqprDQ6IdKCNguBOMaUW6OKEH143h4JV5uMD2dO5OtjLxYD-NMTKdr6-kSacAJYlUy0DzqhXq9OQJLqyHsz4geifto98Yj7cmPBEyewB-NzcjblWKc_dbF3Hly-Sqekpu8V1mW602ysZgv62fkevy1OOnmz5PC_wFaWVqM priority: 102 providerName: ProQuest – databaseName: SpringerLINK Contemporary 1997-Present dbid: RSV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9UwFA86Rfbit646JYrggwZ7mzQfvk1xbIJTtnHZW0jS9joYvaO9FfzvPSdtr3Y6QV-bX6A9OV_pyfmFkBciDT6VlWDSC8VEkI45V6FdcalTV7iKV_GyCXVwoE9OzJehKawdT7uPJcnoqaNZa_mmBU-qDMPtTkzTmbhKrkG402iOh0fzde0AYp4Z22P-OG8SgiJT_-_--JeAdPGw5IWKaQxEu7f-7xNuk5tD4kl3ek25Q66U9V1y49NQWr9HPsZW3KLpFgx24JhV1iu6tz-neAr4jDbgl7q6oH1bIy2RF5m238_xf0z7ljoaIBzSvgJxnxzvfjh-v8eGixZYgP3CisFCmtxprnOfB51VSpXKSSPzigthvDEiFFo7FYwLuePGp77KwD0JXYUMHjwgG_WyLrcIzZ0qkJQwcBmE515LnqXBpTNduEz5PCGzUfQ2DCTkeBfGmY2bES1tLyMLMrJRRlYk5NV6znlPwfFX9Dtc0TUS6bPjg2WzsIM1Whnygvu0yGRRCpfNnMq8K8HX5pDNcl4m5Dnqg0WCjBpP4Cxc17Z2__Pc7khI-CCGz8RloKPDCejlAKqW8KHBDV0PIC4k3pogtydIMPMwHR510w5uprUZN5CvQQaWJuTZehhn4tG5ulx2iIGAhx3IgHnYq_JaOBzbqCHFT4iaKPlEetOR-vRrJCGPRI_aJOT1qOo_X-vy1Xn0b_DHZDPrrYWlaptsrJqufEKuh2-r07Z5Gs3-B7CmUUc priority: 102 providerName: Springer Nature |
| Title | Multidrug-resistant HIV viral rebound during early syphilis: a case report |
| URI | https://link.springer.com/article/10.1186/s12879-020-04999-4 https://www.ncbi.nlm.nih.gov/pubmed/32264923 https://www.proquest.com/docview/2391295210 https://www.proquest.com/docview/2387646280 https://pubmed.ncbi.nlm.nih.gov/PMC7140389 https://doaj.org/article/6c5d3b0d26de4a21a72bae376532633e |
| Volume | 20 |
| WOSCitedRecordID | wos000526233300001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: BioMedCentral customDbUrl: eissn: 1471-2334 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017829 issn: 1471-2334 databaseCode: RBZ dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1471-2334 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017829 issn: 1471-2334 databaseCode: DOA dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1471-2334 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017829 issn: 1471-2334 databaseCode: M~E dateStart: 20010101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1471-2334 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017829 issn: 1471-2334 databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1471-2334 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017829 issn: 1471-2334 databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Publicly Available Content Database customDbUrl: eissn: 1471-2334 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017829 issn: 1471-2334 databaseCode: PIMPY dateStart: 20090101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1471-2334 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017829 issn: 1471-2334 databaseCode: 8C1 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1471-2334 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017829 issn: 1471-2334 databaseCode: RSV dateStart: 20011201 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1bb9MwFLZgIMQL4joCozIIiQeIlsSOL7xt06YVaaXqpqo8WbaTjElTOjUtEv-ec5y0LEODF14iJT6R0nP9XPt8JuQ9T7xLRMVj4biMuRc2trbCuGJCJbawFavCYRNyNFKzmR5fO-oL94S19MCt4naFzwvmkiITRcltllqZOVtCWOQAPBgrMfsC6llPprr1A6h7et0io8RuA1lY6hinSgHix7xXhgJb_585-VpRurlh8saqaShGR4_Jow5F0r3265-QO2X9lDw46dbJn5Evoa-2WKzOY5hOI0Ssl_R4OKW4pfeSLiDJrOqCtj2KtESSY9r8vMI_V5rP1FIPtY22ywnPydnR4dnBcdydmhB7AP_LGKyic6uYyl3uVVZJWUortMgrxrl2WnNfKGWl19bnlmmXuAo0qLiqfAYPXpCtel6XLwnNrSyQYdAz4bljTgmWJd4mqSpsJl0ekXStQ-M7RnE82OLShJmFEqbVuwG9m6B3wyPycfPOVcun8VfpfTTNRhK5sMMD8BDTeYj5l4dE5B0a1iDbRY3bac7tqmnM8OvU7AlAb1CQU36b0OmkJ_ShE6rm8EO97VoYQF3IotWT3OlJQsz6_vDayUyXMxqTMQ3gC-BUEpG3m2F8E_fB1eV8hTJQvbCdGGS2W5_cKIdhTzTg9YjInrf2tNcfqS--B0bxwNqodEQ-rf3692fdbp1X_8M6r8nDrI3LOJE7ZGu5WJVvyH3_Y3nRLAbkrpzJcFVwVQfpgNzbPxyNJ4MQ73A3Hp6Mv8Hd5HT6C8t2U9k |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Zb9QwELZKQcAL9xEoYBCIB4iajR0fSAiVo9qlBxWsqn2zHCdZKlXZZbML6o_iPzLjJFtS1L71gdd4EsX2zDcz9hyEPOeRSyNR8FCkXIbcCRtaW6BcMaEim9mCFb7ZhNzdVaOR3lshv9tcGAyrbDHRA3U2cXhGvh4zDaoJlE30bvojxK5ReLvattCo2WIrP_oFLlv1dvAR9vdFHG9-Gn7oh01XgdCBcTwP4a91YhVTSZo4FRdS5tIKLZKCca5TrbnLlLLSaesSy3QapUUMsshV4WJ4AJ-9QC4CjEuMIJOjpX_XA2Wr27wcJdYrgH6pQ_TPvF8R8o7u8y0C_lUEf2nCk1GaJ65qvQbcvP6frd0Ncq0xtelGLRs3yUpe3iKXd5pggtvks08-zmaLcTjLK7SjyzntD_Ypxj0f0hkg8aLMaJ3ISXOsBE2roymeQFVvqKUODABa37ncIcPzmMhdslpOyvw-oYmVGZZhdEw4nrJUCRZHzkY9ldlYpklAeu2eG9eUXcfuH4fGu19KmJpPDPCJ8XxieEBeLd-Z1kVHzqR-j6y0pMSC4f7BZDY2Df4Y4ZKMpVEWiyznNu5ZGac2B-2SgP3OWB6QZ8iIBkuClBhzNLaLqjKDL_tmQ4CJC1ZLj59G9O1rh-hlQ1RMYKLONnkesFxYaqxDudahBGBz3eGWm00DrJU5ZuWAPF0O45sYLFjmkwXSgIrHnGuguVfL0HJxGCaOg1MTENmRrs7qdUfKg---7Lovbal0QF63cnj8W6fvzoOzZ_GEXOkPd7bN9mB36yG5GtdoEUZyjazOZ4v8Ebnkfs4PqtljjzWUmHOWzz_tErdp |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Zb9QwELagoIqXctNAAYOQeKBRs7Hjg7dyrLocS0WrVd8s20mWSlV2lewi8e-ZcbJLUygS4jUeS8l4zszMZ0Je8MS7RJQ8Fo7LmHthY2tL1CsmVGJzW7IyXDYhx2N1cqIPz03xh273VUmynWlAlKZqsTfPy1bFldhrwKpKHWPqE0L2mF8l1zheGoT5-tFkXUcA_6dXozJ_3NdzRwG1_3fbfM45XWycvFA9DU5pePP_P-cW2eoCUrrfStBtcqWo7pDNz13J_S75EEZ083o5jSEzx2izWtCD0YRid_AZrcFeLauctuOOtEC8ZNr8mON_muY1tdSDm6RtZeIeOR6-P357EHcXMMQe8ohFDAesM6uYylzmVVpKWUgrtMhKxrl2WnOfK2Wl19ZnlmmXuDIFs8VV6VN4cJ9sVLOq2CY0szJHsELPhOeOOSVYmnibDFRuU-myiAxWx2B8B06Od2ScmZCkKGFaHhngkQk8Mjwir9Z75i00x1-p3-DprikRVjs8mNVT02mpET7LmUvyVOQFt-nAytTZAmxwBlEuY0VEnqNsGATOqLAzZ2qXTWNGXyZmX0AgCL59wC8jOvraI3rZEZUz-FBvu2kIYBcCcvUod3qUoP6-v7ySU9OZn8akTEMcB5FZEpFn62XciS11VTFbIg04QpxMBpoHrVivmcNwvBpC_4jInsD3uNdfqU6_BXDyAACpdER2V2L_67UuP52H_0b-lGwevhuaT6Pxx0fkRtoqTpzIHbKxqJfFY3Ldf1-cNvWTYA1-AgrdXQ8 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Multidrug-resistant+HIV+viral+rebound+during+early+syphilis%3A+a+case+report&rft.jtitle=BMC+infectious+diseases&rft.au=Giacomelli%2C+Andrea&rft.au=Micheli%2C+Valeria&rft.au=Cattaneo%2C+Dario&rft.au=Mancon%2C+Alessandro&rft.date=2020-04-07&rft.pub=BioMed+Central+Ltd&rft.issn=1471-2334&rft.eissn=1471-2334&rft.volume=20&rft.issue=1&rft_id=info:doi/10.1186%2Fs12879-020-04999-4&rft.externalDocID=A627329914 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2334&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2334&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2334&client=summon |